Clinical Trial Update: Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial update for diflomotecan (BN80915) given every 3 weeks in sensitive small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• BN80915 (diflomotecan)
• diflomotecan (diflomotecan)

Snippet

Sponsor: Ipsen | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED